Shares of Amgen dropped nearly 5% after the release of disappointing results from a study on their weight-loss drug, MariTide. The drug showed promising weight loss and cardiometabolic improvements but caused side effects. Despite optimism from Amgen, investors were not impressed.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing